Wyniki wyszukiwania - Biblioteka Nauki

Nowa wersja platformy, zawierająca wyłącznie zasoby pełnotekstowe, jest już dostępna.
Przejdź na https://bibliotekanauki.pl

Ograniczanie wyników

Znaleziono wyników: 2

Liczba wyników na stronie

Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych: leki nootropowe

Sortuj według:

Ogranicz wyniki do:

Kierunki poszukiwania nowych leków wpływających na procesy uczenia i zapamiętywania, poprawiających rozpoznawanie

100%

Malawska B.

Wiadomości Chemiczne

2001

tom [Z] 55, 1-2

67-92

This review attempts to briefly summarise the recent developments in the study of new compounds improving learning, memory and cognitive function. A large number of compounds belonging to many different chemical classes have been proposed as cognition enhancers. Three groups of compounds - nootropics, cholinergic drugs and neuromodulators are presented . Most compounds described as nootrpics are 2-pyrrolidone derivatives, the prototype of which is piracetam (Nootropil) . Nootropics facilitate learning and memory in animal models. Clinical trials have yielded unconvincing results, however some new drugs such as nefiracetam and fasoracetam appear promising. Central cholinergic systems have been repeatedly shown to play an important role in learning and memory. The deficits in cognitive and memory performance observed in aged humans and in Alzheimer's disease (AD) patients are due at least in part to deficient cholinergic functioning. Augmentation of cholinergic neurotransmission might be accomplished in several different ways. Cholinergic agonists directly acting on muscarinic receptors may improve the defective cholinergic function seen in AD. Selective second-generation muscarinic agonists appear promising and are in various stages of preclinical and clinical evaluation, including milameline, itameline, xanomeline, sabcomeline and talsaclidine. These compounds are chemically related to the naturally occurring muscarinic agonist, arecoline. The prototypical neuronal acetylcholine receptors agonist nicotine has been shown to ameliorate some of the symptoms of AD, and, in a number of animal models, to have neuroprotective effects. Some nicotinic agonists were reported to be active in animal models of memory and learning, such as compounds ABT-418, ABT-089 and SIB-1553A . Acetylcholinesterase (AChE) inhibition is presently the most successful method to ameliorate cholinergic deficit and lead to symptomatic improvement. About 30 AChE inhibitors are currently being studied word-wide in preclinical or clinical studies. AChE inhibitors are broadly classified in three categories. These include: the carbamates such as physostigmine, eptastigmine, phenserine and rivastigmine; the aminoacridines such as tacrine, velnacrine, suronacrine, and their derivatives ipidacrine and compound SM-10888 ; the benzylpiperidines such as donepezil, T-82, TAK-147 and CP-118954. Tacrine was the the first drug approved in 1993 in USA for treatment of senile dementia of the Alzheimer type. Rivastigmine, and donepezil were approved in 1997. Cymserine and bis-norcimserine are derivatives of the alkaloid physostigmine. These compounds represent the first available potent, reversible, and selective inhibitors of butyrylcholinesterase. The organophosphate metrifonate has been extensively studied in animals and recently evaluated in AD. Metrifonat is an inactive prodrug, but is non-enzymatically transformed into the active compound dichlorvos that irreversibly inhibits AChE. There are many reports on the interaction between the cholinergic system and other putative neurotransmitter on the central nervous system. Therefore, such transmitter interactions play an important role in the regulation of learning and memory. Modulators, the third group of compounds represents different structures. A wide variety of substances have been shown to facilitate memory, including: opioid agonist (SA 4503), a benzodiazepine inverse agonist (S-8510), modulator of noradrenergic transmission (CR 2249) ; derivatives of piperazine (FK-960, ensaculine) and peptides (NC-1900) .

Nootropic drugs Method supporting memory and concentration at work and studies

72%

Modrzyński R. J.

Rozprawy Społeczne

2021

tom 15

nr 2

117-125

Streszczenie Współczesne pokolenie często nazywane jest „natychmiastowym”, co charakteryzuje się potrzebą natychmiastowej gratyfikacji. W tej rzeczywistości sukces zależy od umiejętności poznawczych. Pomimo tego, że leki nootropowe, czyli naturalne i syntetyczne substancje poprawiające procesy poznawcze, takie jak koncentracja, pamięć, uczenie się i motywacja, są powszechnie stosowane w leczeniu pacjentów z zespołem deficytu uwagi (ADHD), pacjentów z padaczką po udarze mózgu czy osób cierpiących na demencję, ich prawdziwa „kariera” rozpoczyna się, gdy osoby zdrowe, w szczególności studenci i pracownicy wymagających zawodów, zaczęły używać tych leków. Artykuł porusza kwestię leków nootropowych. Przedstawiono najpopularniejsze neurostymulanty wraz z opisem ich działania i częstością ich stosowania. Autor dokonuje również przeglądu skuteczności leków nootropisowych na podstawie dostępnych badań naukowych w literaturze przedmiotu. Artykuł kończy się refleksją nad przyszłością neurostymulantów. Materiał i metody nd. Wyniki nd. Wnioski nd.

Abstract The modern generation is often called "instant", which is characterized by the need for immediate gratification. In this reality, success depends on cognitive skills. Despite the fact that nootropic drugs, i.e. natural and synthetic substances that improve cognitive processes, such as concentration, memory, learning and motivation, are commonly used in the treatment of patients suffering from attention deficit disorder (ADHD), patients with epilepsy, after stroke of the brain or people suffering from dementia, their real "career" comes when healthy people started using these drugs, in particular students and employees of demanding professions. The article addresses the issue of nootropics drugs. The most popular neurostimulants are presented, along with a description of their action and their prevalence of use. The author also reviews the effectiveness of nootropis drugs basing on available scientific research in the subject literature. The article ends with a reflection on the future of neurostimulants. Material and methods NA Results NA Conclusions NA